

New Sesquiterpenoids from *Ligularia duciformis*


by Wen-Shu Wang*, Xia Dai, Li-Ya Hong, Peng Lu, Jin-Chao Feng, and Yu-Guo Jiao

College of Life and Environment Science, Central University for Nationalities, Beijing 100081, P. R. China (phone: +86-10-68932633; fax: +86-10-68936927; e-mail: wangwshu@hotmail.com)

From the whole plants of *Ligularia duciformis*, four new sesquiterpenoids, 3 β -acetoxy-6 β -methoxyeremophila-7(11),9(10)-dien-12,8 β -olide (**1**), 3 β -acetoxy-8 α -hydroxy-6 β -methoxyeremophila-7(11),9(10)-dien-12,8 β -olide (**2**), 3 β -acetoxy-10 β -hydroxy-6 β ,8 β -dimethoxyeremophil-7(11)-en-12,8 α -olide (**3**), and 3 β -acetoxy-6 β ,8 β ,10 β -trihydroxyeremophil-7(11)-en-12,8 α -olide (**4**) were isolated. Their structures were established by high-field NMR techniques (¹H,¹H-COSY, ¹³C-APT, HMQC, HMBC, and NOESY) and HR-ESI-MS analysis, together with comparison of the spectroscopic data with those of structurally related compounds. In addition, the cytotoxicity of the new compounds against human hepatic cancer cells Bel-7402, human pneumonic cancer cells A-549, and human colonic cancer cells HCT-8 were evaluated, the new compounds showed no cytotoxicity against the three tumor cells (all IC₅₀ values > 200 μ M).

Introduction. – *Ligularia duciformis* (Compositae) is a perennial grass, which is native in the southwest area of mainland China. Its roots are used as a Chinese folk medicine for the treatment of inflammation and apoplexy [1], showing effect on nourishing lung and relieving a cough. Sesquiterpenoids, especially eremophil-7(11)-en-12,8-olides have been isolated from other plants in *Ligularia* as the characteristic components of the genus [2–4]. However, phenolic compounds were previously reported from the dried root of *L. duciformis* collected in Hubei Province [5]. Herein, we studied the constituents of the MeOH extract of the whole plant of *L. duciformis*, collected in the southwest area of Sichuan Province, where the average height is more than 3000 meters. As a result, four new eremophil-7(11)-en-12,8-olides **1–4** were isolated. In this work, we describe the isolation and structural elucidation of these compounds. Furthermore, all new compounds were evaluated for their cytotoxicity against human hepatic cancer cells Bel-7402, human pneumonic cancer cells A-549, and human colonic cancer cells HCT-8.

Results and Discussion. – Compound **1** was obtained as colorless needles. Its molecular formula was deduced as C₁₈H₂₄O₅ from HR-ESI-MS ($[M+H]^+$ at m/z 321.1691), and showed seven degrees of unsaturation. The IR spectrum showed absorptions of an α,β -unsaturated γ -lactone (1741 cm⁻¹) and an AcO group (1710 cm⁻¹), as well as of a C=C bond (1610 cm⁻¹). The ¹³C-NMR spectrum displayed 18 C-atoms including five Me, two CH₂, and five CH groups, as well as six quaternary C-atoms, assigned by an APT experiment. Additionally to two C=O groups with signals at $\delta(C)$ 173.80 and $\delta(C)$ 170.77, and two C=C bonds with signals at $\delta(C)$ 157.82, $\delta(C)$ 120.70, $\delta(C)$ 148.57, and $\delta(C)$ 118.00 in the ¹³C-NMR spectrum, the compound should



consist of three rings to satisfy the degrees of unsaturation. In the $^1\text{H-NMR}$ spectrum, an AcO signal at $\delta(\text{H})$ 2.06 (s) and a MeO signal at $\delta(\text{H})$ 3.46 (s) could be observed. Based on the above data and comparison of the spectral data with those of reported eremophilanolides, the structure was proposed to be an eremophil-7(11)-en-12,8-olide [6]. Assignments of the ^1H - and ^{13}C -NMR data (Tables 1 and 2) were based on an HMQC experiment. In the $^1\text{H}, ^1\text{H-COSY}$ spectrum, Me(15) ($\delta(\text{H})$ 1.15) showed a correlation with $\text{H}_\alpha\text{-C}(4)$ ($\delta(\text{H})$ 1.92–1.99), and $\text{H}_\alpha\text{-C}(4)$ showed a correlation with $\text{H}_\alpha\text{-C}(3)$ ($\delta(\text{H})$ 4.94), while $\text{H-C}(9)$ ($\delta(\text{H})$ 5.61) showed a correlation with $\text{H}_\alpha\text{-C}(1)$ ($\delta(\text{H})$ 2.46–2.53) and $\text{H-C}(8)$ ($\delta(\text{H})$ 5.28), respectively. In the HMBC spectrum, $\text{H}_\alpha\text{-C}(3)$ showed a correlation with the C-atom at $\delta(\text{C})$ 170.77 of the AcO group, $\text{H-C}(9)$ showed correlations with $\text{C}(7)$ ($\delta(\text{C})$ 157.82) and $\text{C}(5)$ ($\delta(\text{C})$ 50.12). Thus, the AcO group should be attached to $\text{C}(3)$, and the second $\text{C}=\text{C}$ bond should be between $\text{C}(9)$ and $\text{C}(10)$ (Fig. 1). The relative configuration at $\text{C}(3)$ was established as β -oriented (orientation of the AcO group) by the small coupling constants between $\text{H}_\alpha\text{-C}(3)$ (equatorial bond) and $\text{CH}_2(2)$ and $\text{H}_\alpha\text{-C}(4)$ ($J(3\alpha,2\beta)=2.5$, $J(3\alpha,2\alpha)=J(3\alpha,4\alpha)=3.0$). The cross-peaks of $\text{H}_\alpha\text{-C}(6)$ and $\text{H}_\alpha\text{-C}(4)$, and $\text{H}_\alpha\text{-C}(6)$ and $\text{H}_\alpha\text{-C}(8)$ in the NOESY spectrum indicated that the MeO group at $\text{C}(6)$ and the α,β -unsaturated lactone at $\text{C}(8)$ were both β -oriented (Fig. 2). Therefore, compound **1** was elucidated as 3β -acetoxy- 6β -methoxyeremophila-7(11),9(10)-dien-12,8 β -olide.




Fig. 1. Key HMBC correlations of compounds **1** and **3**

Compound **2** was obtained as a colorless oil. Its molecular formula was assigned as $\text{C}_{18}\text{H}_{24}\text{O}_6$ on the basis of the HR-ESI-MS ($[M + \text{Na}]^+$ at m/z 359.1463). The ^1H - and ^{13}C -NMR spectra (Tables 1 and 2) were close to those of **1**. However, no $\text{H-C}(8)$ H-

Table 1. $^1\text{H-NMR}$ Data of Compounds **1–4** (500 MHz, (D_6) acetone, δ in ppm)

	1	2	3	4
$\text{H}_\alpha\text{-C(1)}$	2.46–2.53 (<i>m</i>)	2.46–2.50 (<i>m</i>)	1.85–1.93 (<i>m</i>)	2.13–2.18 (<i>m</i>)
$\text{H}_\beta\text{-C(1)}$	2.05–2.09 (<i>m</i>)	2.01–2.03 (<i>m</i>)	1.22–1.27 (<i>m</i>)	1.43–1.49 (<i>m</i>)
$\text{H}_\alpha\text{-C(2)}$	1.55–1.64 (<i>m</i>)	1.59–1.66 (<i>m</i>)	1.72–1.79 (<i>m</i>)	1.78–1.87 (<i>m</i>)
$\text{H}_\beta\text{-C(2)}$	1.95–2.03 (<i>m</i>)	1.94–2.03 (<i>m</i>)	1.66–1.70 (<i>m</i>)	1.59–1.66 (<i>m</i>)
H-C(3)	4.94 (<i>dt</i> , $J=3.0, 2.5$)	4.94 (<i>dt</i> , $J=3.0, 2.5$)	4.87 (<i>dt</i> , $J=2.5, 1.5$)	4.90 (<i>dt</i> , $J=3.0, 1.5$)
H-C(4)	1.92–1.99 (<i>m</i>)	1.98–2.02 (<i>m</i>)	1.67–1.72 (<i>m</i>)	1.31–1.36 (<i>m</i>)
H-C(6)	4.23 (<i>q</i> , $J=1.0$)	4.24 (<i>q</i> , $J=1.0$)	4.39 (<i>s</i>)	4.70 (<i>s</i>)
H-C(8)	5.28 (<i>d</i> , $J=1.5$)	–	–	–
$\text{H}_\alpha\text{-C(9)}$	5.61 (<i>t</i> , $J=1.5$)	5.74 (<i>d</i> , $J=1.0$)	2.40 (<i>d</i> , $J=15$)	2.37 (<i>d</i> , $J=15$)
$\text{H}_\beta\text{-C(9)}$	–	–	2.22 (<i>d</i> , $J=15$)	2.22 (<i>d</i> , $J=15$)
Me(13)	1.93 (<i>d</i> , $J=1.0$)	1.94 (<i>d</i> , $J=1.0$)	1.96 (<i>s</i>)	1.88 (<i>s</i>)
Me(14)	1.14 (<i>s</i>)	1.14 (<i>s</i>)	1.36 (<i>s</i>)	1.43 (<i>s</i>)
Me(15)	1.15 (<i>d</i> , $J=7.0$)	1.14 (<i>d</i> , $J=7.0$)	0.96 (<i>d</i> , $J=7.0$)	0.91 (<i>d</i> , $J=8.0$)
6-MeO	3.46 (<i>s</i>)	3.43 (<i>s</i>)	3.40 (<i>s</i>)	–
8-MeO	–	–	3.24 (<i>s</i>)	–
AcO	2.06 (<i>s</i>)	2.06 (<i>s</i>)	2.05 (<i>s</i>)	2.11 (<i>s</i>)

Table 2. $^{13}\text{C-NMR}$ Data of Compounds **1–4** (125 MHz, (D_6) acetone, δ in ppm)

	1	2	3	4
$\text{CH}_2(1)$	26.90 (<i>t</i>)	26.79 (<i>t</i>)	29.68 (<i>t</i>)	27.47 (<i>t</i>)
$\text{CH}_2(2)$	31.05 (<i>t</i>)	30.95 (<i>t</i>)	26.76 (<i>t</i>)	31.00 (<i>t</i>)
H-C(3)	74.29 (<i>d</i>)	74.29 (<i>d</i>)	72.77 (<i>d</i>)	72.40 (<i>d</i>)
H-C(4)	45.67 (<i>d</i>)	45.61 (<i>d</i>)	35.54 (<i>d</i>)	36.47 (<i>d</i>)
C(5)	50.12 (<i>s</i>)	50.29 (<i>s</i>)	47.81 (<i>s</i>)	46.97 (<i>s</i>)
H-C(6)	86.76 (<i>d</i>)	85.95 (<i>d</i>)	80.21 (<i>d</i>)	70.76 (<i>d</i>)
C(7)	157.82 (<i>s</i>)	156.75 (<i>s</i>)	151.36 (<i>s</i>)	154.39 (<i>s</i>)
H-C(8) or C(8)	77.54 (<i>d</i>)	100.86 (<i>s</i>)	106.41 (<i>s</i>)	103.23 (<i>s</i>)
$\text{H-C(9) or CH}_2(9)$	118.00 (<i>d</i>)	119.86 (<i>d</i>)	41.80 (<i>t</i>)	43.55 (<i>t</i>)
C(10)	148.57 (<i>s</i>)	148.87 (<i>s</i>)	73.68 (<i>s</i>)	76.77 (<i>s</i>)
C(11)	120.70 (<i>s</i>)	122.11 (<i>s</i>)	131.48 (<i>s</i>)	126.40 (<i>s</i>)
C(12)	173.80 (<i>s</i>)	170.97 (<i>s</i>)	170.70 (<i>s</i>)	170.92 (<i>s</i>)
Me(13)	7.91 (<i>q</i>)	7.47 (<i>q</i>)	8.05 (<i>q</i>)	8.74 (<i>q</i>)
Me(14)	13.90 (<i>q</i>)	13.82 (<i>q</i>)	12.28 (<i>q</i>)	12.57 (<i>q</i>)
Me(15)	14.64 (<i>q</i>)	14.00 (<i>q</i>)	12.03 (<i>q</i>)	12.25 (<i>q</i>)
6-MeO	56.99 (<i>q</i>)	56.84 (<i>q</i>)	58.70 (<i>q</i>)	–
8-MeO	–	–	50.27 (<i>q</i>)	–
AcO	20.20, 170.77	20.21, 169.97	20.29, 170.60	21.28, 170.92

atom was observed in the $^1\text{H-NMR}$ spectrum, and a signal for a dioxygenated quaternary C-atom at $\delta(\text{C})$ 100.86 in the $^{13}\text{C-NMR}$ spectrum was observed instead of the signal at $\delta(\text{C})$ 77.54 in the spectrum of **1**. The IR spectrum showed an absorption for a OH group at 3454 cm^{-1} , in addition to absorptions for an α,β unsaturated γ -lactone at 1733 cm^{-1} , an AcO group at 1715 cm^{-1} , and a C=C bond at 1669 cm^{-1} . Based on the above data, compound **2** could be deduced as 3-acetoxy-8-hydroxy-6-methoxyremophila-7(11),9(10)-dien-12,8-olide. The coupling pattern of the $^1\text{H-NMR}$ signal of H-C(3) ($\delta(\text{H})$ 4.94, *dt*, $J=3.0, 2.5$) also showed that the AcO group has β -orientation.




Fig. 2. Important NOESY correlations of compounds **1** and **3**

The cross-peaks between H_α -C(4) and H-C(6) in the NOESY spectrum indicated a β -orientated MeO group. Due to the presence of a homoallylic coupling between H_α -C(6) ($\delta(H)$ 4.24, q , $J=1.0$) and Me(13) ($\delta(H)$ 1.94, d , $J=1.0$), the relative configuration of the OH group at C(8) was established to be α , from which the angle between H_α -C(6) and Me(13)-C(11) could be determined to be *ca.* 90° [7][8]. Therefore, compound **2** was elucidated as 3β -acetoxy- 8α -hydroxy- 6β -methoxyeremophila-7(11),9(10)-dien-12,8 β -olide.

Compound **3** was obtained as colorless needles. Its molecular formula was determined as $C_{19}H_{28}O_7$ by HR-ESI-MS ($[M+Na]^+$ at m/z 391.1728). Its 1H - and ^{13}C -NMR spectra were similar to the data of compounds **1** and **2** (Tables 1 and 2). Differences were found for an oxygenated quaternary C-atom at $\delta(C)$ 73.68 and a secondary C-atom $\delta(C)$ 41.80 in the ^{13}C -NMR, instead of the $\Delta^{9(10)}$ C=C signals of **1** and **2**. Furthermore, an additional MeO signal was observed at $\delta(H)$ 3.24 (s) in the 1H -NMR spectrum, corresponding to the second MeO C-atom at $\delta(C)$ 50.27 in the ^{13}C -NMR spectrum. In accordance with the IR absorptions for an OH group at 3536 cm^{-1} , for an α,β -unsaturated γ -lactone at 1772 cm^{-1} , and for an AcO group at 1733 cm^{-1} , compound **3** should be deduced as 3-acetoxy-6,8-dimethoxyeremophil-7(11)-en-12,8-olide. Its 1H - and ^{13}C -NMR signals were assigned by an HMQC experiment, which was similar with the reported 3β -acetoxy- $8\beta,10\beta$ -dihydroxy- 6β -methoxyeremophilenolide [9]. The MeO-C(8) bond was confirmed by the cross-peak between the signal of the MeO group at $\delta(H)$ 3.24 and C(8) $\delta(C)$ 106.41 in the HMBC experiment (Fig. 1). Rules about the relative configuration at C(8) reported by Naya *et al.* indicate that in $12,8\alpha$ -eremophilenolides, the *singlet* of Me(14) appears in a lower field in the 1H -NMR spectrum than the *doublet* of Me(15), while in $12,8\beta$ -eremophilenolide, the signals are found *vice versa* [10]. Thus, the 1H -NMR data of compound **3** indicated an $12,8\alpha$ -eremophilenolide. Furthermore, the absence of a homoallylic coupling between Me(13)-C(11) and H_α -C(6) in the $12,8\alpha$ -olide showed that the MeO group at C(6) was β -orientated, as the angle between H_α -C(6) and Me(13)-C(11) was around 0° [8]. The upfield signal for Me(15) also indicates a *cis*-eremophilane skeleton, supporting a β -orientation of the OH group at C(10) [11][12], confirmed by the key cross peaks in the NOESY spectrum (Fig. 2). As a result, compound **3** was elucidated as 3β -acetoxy- 10β -hydroxy- $6\beta,8\beta$ -dimethoxyeremophil-7(11)-en-12,8 α -olide.

Compound **4** was obtained as colorless needles. Its molecular formula was determined as $C_{17}H_{24}O_7$ by the $[M+NH_4]^+$ peak in HR-ESI-MS ($[M+NH_4]^+$ at m/z 358.1862). The IR spectrum showed absorptions for two OH groups at 3493 and

3325 cm^{-1} , an α,β -unsaturated γ -lactone at 1750 cm^{-1} , and an AcO group at 1711 cm^{-1} . The ^1H - and ^{13}C -NMR spectra were very similar to those of compound **3** (Tables 1 and 2), except for the absence of two MeO groups. The ^1H - and ^{13}C -NMR data were also assigned by an HMQC experiment. The AcO group was attached to C(3) as deduced by the cross peak between the AcO C-atom ($\delta(\text{C})$ 170.92) and H–C(3) ($\delta(\text{H})$ 4.90, *dt*, $J = 3.0, 1.5$). Furthermore, compared with compound **3**, the three OH groups in **4** were attached to C(6), C(8), and C(10) respectively. The small coupling constants of $J(3\alpha,2\alpha)$, $J(3\alpha,2\beta)$, and $J(3\alpha,4\alpha)$ indicated that H–C(3) was in equatorial position, which indicated that the AcO-group at C(3) had β -orientation. The relative configuration at C(8) was deduced as 12,8 α -olide by the difference between chemical shifts of Me(14) and Me(15) (Table 1). The absence of a homoallylic coupling between H_α –C(6) and Me(13)–C(11) showed that the 6-OH group was in β -orientation. The upfield Me(15) also implied a *cis*-eremophilane, showing the 10-OH group in β -orientation [11][12]. Thus, compound **4** was elucidated as 3 β -acetoxy-6 β ,8 β ,10 β -trihydroxyeremophil-7(11)-en-12,8 α -olide.

Erremophilanides **1–4** were tested for their cytotoxicity against human hepatic cancer cells Bel-7402, human pneumonic cancer cells A-549, and human colonic cancer cells HCT-8, using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) method [13]. The results showed that compounds **1–4** do not have the ability to inhibit the tumor cells (all IC_{50} values $> 200 \mu\text{M}$).

Experimental Part

General. TLC: precoated SiO_2 GF₂₅₄ plates (Qingdao Marine Chemical Factory P. R. China). Column chromatography (CC): SiO_2 (200–300 mesh; Qingdao Marine Chemical Factory, P. R. China); Sephadex LH-20 (Pharmacia). M.p.: X-6 micro-melting-point apparatus; uncorrected. Optical rotation: Perkin-Elmer 341 polarimeter. UV Spectra: HITACHI-U-2800 UV/VIS spectrophotometer; λ_{max} (log ϵ) in nm. IR Spectra (KBr): Bruker-VERTEX 70 FT-IR spectrometer; in cm^{-1} . 1D- and 2D-NMR Spectra: Bruker-AV-500 spectrometer; δ in ppm rel. to Me_4Si , J in Hz. MS: Agilent-1100-LC/MSD-Trap SL (ESI-MS) and Bruker APEX II (HR-ESI-MS) mass spectrometer; in *m/z*.

Plant Material. The whole plants of *L. duciformis* were collected in Meigu County, Sichuan Province, P. R. China, in August 2006. The plant material was identified by Prof. Yi-Lin Chen, Institute of Botany, Chinese Academy of Sciences, P. R. China. A voucher specimen (No. 20060901) was deposited in the herbarium of the College of Life and Environment, Central University of Nationalities, Beijing, P. R. China.

Extraction and Isolation. The air-dried whole plants of *L. duciformis* (1.5 kg) were pulverized and extracted three times with MeOH (each for 7 d) at r.t. The extract was concentrated to give a residue (110 g), which was further separated by CC (SiO_2 , petroleum ether (PE)/AcOEt 30:1, 20:1, 15:1, 10:1, 8:1, 5:1, 3:1, 2:1, 1:1, 1:1.5 (v/v)): Fr. 1–10. Each fraction was examined by TLC and combined to afford many subfractions. Fr. 6a (0.9 g) was subjected to CC (SiO_2 , PE/AcOEt 10:1, 5:1 (v/v)) to yield **1** (20 mg). Fr. 7a (1.0 g) was purified by CC (SiO_2 , PE/AcOEt 8:1, 5:1 (v/v)) to yield **2** (18 mg). Fr. 8a (1.4 g) was subjected to CC (SiO_2 , PE/AcOEt 8:1, 5:1 (v/v)) to give a crude gum of **3**, which was further purified by CC (Sephadex LH-20, MeOH) to yield **3** (15 mg). Fr. 9c (0.8 g) was separated by CC (SiO_2 , PE/AcOEt 5:1, 3:1 (v/v)) to give a crude gum of **4**, which was further purified by CC (Sephadex LH-20, MeOH) to give **4** (30 mg).

3 β -Acetoxy-6 β -methoxyeremophila-7(11),9(10)-dien-12,8 β -olide (= (4S,4aR,5R,6S,9aR)-6-(Acetyloxy)-4a,5,6,7,8,9a-hexahydro-4-methoxy-3,4a,5-trimethylnaphtho[2,3-b]furan-2(4H)-one; **1**). Colorless needles. M.p. 219.0–220.8° (Me_2CO). $[\alpha]_{\text{D}}^{25} = -139$ ($c = 0.002$, CHCl_3). UV (MeOH): 218 (3.84). IR (KBr): 1741, 1710, 1610, 1443, 1385, 1251. ^1H - and ^{13}C -NMR: Tables 1 and 2. ESI-MS (pos.): 343.2 ($[M + \text{Na}]^+$). HR-ESI-MS: 321.1691 ($[M + \text{H}]^+$, $\text{C}_{18}\text{H}_{25}\text{O}_5^+$; calc. 321.1702).

3β-Acetoxy-8α-hydroxy-6β-methoxyeremophila-7(11),9(10)-dien-12,8β-olide (= (4S,4aR,5R,6-S,9aR)-6-(Acetyloxy)-4a,5,6,7,8,9a-hexahydro-9a-hydroxy-4-methoxy-3,4a,5-trimethylnaphtho[2,3-b]furan-2(4H)-one; **2**). Colorless oil. $[\alpha]_D^{25} = -12$ ($c = 0.001$, CHCl₃). UV (MeOH): 234 (3.49). IR (KBr): 3454, 1733, 1715, 1669, 1456, 1377, 1247. ¹H- and ¹³C-NMR: *Tables 1* and *2*. ESI-MS (pos.): 359.1 ($[M + Na]^+$). HR-ESI-MS: 359.1463 ($[M + Na]^+$, C₁₈H₂₄NaO₆⁺; calc. 359.1471).

3β-Acetoxy-10β-hydroxy-6β,8β-dimethoxyeremophil-7(11)-en-12,8α-olide (= (4S,4aS,5R,6S,8a-S,9aS)-6-(Acetyloxy)-4a,5,6,7,8,8a,9,9a-octahydro-8a-hydroxy-4,9a-dimethoxy-3,4a,5-trimethylnaphtho[2,3-b]furan-2(4H)-one; **3**). Colorless, needles. M.p. 218.5–219.0° (Me₂CO). $[\alpha]_D^{25} = +98$ ($c = 0.001$, CHCl₃). UV (MeOH): 224 (3.68). IR (KBr): 3536, 1772, 1733, 1450, 1379, 1250. ¹H- and ¹³C-NMR: *Tables 1* and *2*. ESI-MS (pos.): 391.2 ($[M + Na]^+$). HR-ESI-MS: 391.1728 ($[M + Na]^+$, C₁₉H₂₈NaO₇⁺; calc. 391.1733).

3β-Acetoxy-6β,8β,10β-trihydroxyeremophil-7(11)-en-12,8α-olide (= (4S,4aS,5R,6S,8aS,9aS)-6-(Acetyloxy)-4a,5,6,7,8,8a,9,9a-octahydro-4,8a,9a-trihydroxy-3,4a,5-trimethylnaphtho[2,3-b]furan-2(4H)-one; **4**). Colorless, needles. M.p. 192.4–192.7° (Me₂CO). $[\alpha]_D^{25} = +54.4$ ($c = 0.001$, CHCl₃). UV (MeOH): 220 (3.54). IR (KBr): 3492, 3325, 1750, 1711, 1439, 1390, 1262. ¹H- and ¹³C-NMR: *Tables 1* and *2*. ESI-MS (pos.): 363.2 ($[M + Na]^+$). HR-ESI-MS: 358.1862 ($[M + NH_4]^+$, C₁₇H₂₈NO₇⁺; calc. 358.1866).

Test of Cytotoxicities against Human Hepatic Cancer Cells Bel-7402, Human Pneumonic Cancer Cells A-549, and Human Colonic Cancer Cells HCT-8. Cells were seeded into 96 well plates at a density of 10⁴ cells per well in growth medium. The plates were incubated at 37° under the condition of humidified atmosphere containing 5% CO₂. After 24 h, the medium was discarded and test solns. were added. Five wells were used for each concentration and cell controls. After 72 h incubation at 37°, the medium was removed and 200 μl of MTT solution (0.5 mg MTT dissolved into 1 ml *Dulbecco's Modified Eagle's Medium* (DMEM)) were added to each well. After four h at 37°, the supernatant was removed and the formazan product was solubilized by the addition of 200 μl DMSO. The optical density of each well was measured using an automatic plate reader (*Multiscan MK3*) with the test wavelength of 570 nm. The absorbance was directly proportional to the number of living cells. The cytotoxicity of each compound was expressed as an IC₅₀ value, *i.e.*, the concentration in μM that inhibits cell growth by 50% compared with cell controls, and was calculated by linear regression analysis.

This work was financially supported by the '985 Project' (CUN985-03-03) Central University for Nationalities and the *Project for Young Teachers in Central University for Nationalities* CUN10A, together with the '*Programme of Introducing Talents of Discipline to Universities* (B08044)'.

REFERENCES

- [1] Beijing Institute of Botany, Chinese Academy of Sciences, 'Iconographia Cormophytorum Sinicorum Tomus IV', Science Press, Beijing, 1975, p. 579.
- [2] Z. Jia, Y. Zhao, R. Tan, *J. Nat. Prod.* **1993**, *56*, 494.
- [3] W. S. Wang, K. Gao, L. Yang, Z. J. Jia, *Planta Med.* **2000**, *66*, 189.
- [4] Q.-X. Wu, Y.-P. Shi, L. Yang, *Planta Med.* **2004**, *70*, 479.
- [5] K. Gao, W.-S. Wang, Z.-J. Jia, *Phytochemistry* **1998**, *47*, 269.
- [6] M. Mao, Z. Jia, *Planta Med.* **2002**, *68*, 55.
- [7] K. Naya, R. Kanazawa, M. Sawada, *Bull. Chem. Soc. Jpn.* **1975**, *48*, 3220.
- [8] Y. Moriyama, T. Takahashi, *Bull. Chem. Soc. Jpn.* **1976**, *49*, 3196.
- [9] S. Zhang, G. Zhao, R. Li, G. Lin, *Phytochemistry* **1998**, *48*, 519.
- [10] K. Naya, N. Nogi, Y. Makiyama, H. Takashina, T. Imagawa, *Bull. Chem. Soc. Jpn.* **1977**, *50*, 3002.
- [11] K. Naya, T. Matsuura, M. Makiyama, M. Tsumura, *Heterocycles* **1978**, *10*, 177.
- [12] G. Massiot, J.-M. Nuzillard, L. Le Men-Olivier, P. Aclinou, A. Benkouider, A. Khelifa, *Phytochemistry* **1990**, *29*, 2207.
- [13] R. Han, 'Research and Development of Anticancer Drugs and Experimental Techniques', Associated Press of Beijing Medical University and Xiehe Medical University of China, Beijing, 1997.

Received January 28, 2008